Stock Price, News, Quote and Profile of RENALYTIX AI PLC-ADR(NASDAQ:RNLX) stock

RENALYTIX AI PLC-ADR

NASDAQ:RNLX (10/7/2024, 8:16:27 PM)

After market: 0.13 -0.08 (-37.23%)

0.2071

+0.01 (+5.66%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryHealth Care Technology

GICS SubIndustryHealth Care Technology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%74.99%

Sales Q2Q%-68.35%

CRS2.66

6 Month-76.81%

Overview

Earnings (Last)05-15 2024-05-15/bmo

Earnings (Next)10-29 2024-10-29/amc

Ins Owners6.06%

Inst Owners4.26%

Market Cap17.18M

Shares82.96M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts84

Short Float %N/A

Short RatioN/A

IPO11-06 2018-11-06

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Company Info

RENALYTIX AI PLC-ADR

Finsgate, 5-7 Cranwood Street

London SOUTH GLAMORGAN CF64 2EZ

P: 442920710570

CEO: James McCullough

Employees: 102

Website: https://renalytix.com/

RNLX News

3 months ago - Renalytix plcCommencement of trading on OTCQB in the United States

Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024

3 months ago - Renalytix plcCommencement of trading on OTCQB in the United States

Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024...

6 months ago - Renalytix plcRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics...

6 months ago - Renalytix plcRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”